{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:50:07Z","timestamp":1771617007467,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2013.4","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T14:17:39Z","timestamp":1363961859000},"page":"e106-e106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model"],"prefix":"10.1038","volume":"3","author":[{"given":"S","family":"Schiffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H P","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hehmann-Titt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Thepen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"BFbcj20134_CR1","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/j.1349-7006.2009.01192.x","volume":"100","author":"M Mathew","year":"2009","unstructured":"Mathew M, Verma RS . Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100: 1359\u20131365.","journal-title":"Cancer Sci"},{"key":"BFbcj20134_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00280-011-1573-4","volume":"68","author":"I Kanatani","year":"2011","unstructured":"Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH et al. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol 2011; 68: 979\u2013990.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbcj20134_CR3","doi-asserted-by":"publisher","first-page":"13799","DOI":"10.1073\/pnas.0801724105","volume":"105","author":"FC Kurschus","year":"2008","unstructured":"Kurschus FC, Fellows E, Stegmann E, Jenne DE . Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci USA 2008; 105: 13799\u201313804.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj20134_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.0105-2896.2010.00894.x","volume":"235","author":"FC Kurschus","year":"2010","unstructured":"Kurschus FC, Jenne DE . Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010; 235: 159\u2013171.","journal-title":"Immunol Rev"},{"key":"BFbcj20134_CR5","first-page":"1341","volume":"2","author":"Y Liu","year":"2003","unstructured":"Liu Y, Cheung LH, Hittelman WN, Rosenblum MG . Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2003; 2: 1341\u20131350.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj20134_CR6","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-08-0554","volume":"7","author":"B Stahnke","year":"2008","unstructured":"Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7: 2924\u20132932.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj20134_CR7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4161\/cbt.7.8.6261","volume":"7","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhao J, Wang T, Yu CJ, Jia LT, Duan YY et al. HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol Ther 2008; 7: 1226\u20131231.","journal-title":"Cancer Biol Ther"},{"key":"BFbcj20134_CR8","doi-asserted-by":"publisher","first-page":"21343","DOI":"10.1074\/jbc.M312648200","volume":"279","author":"J Zhao","year":"2004","unstructured":"Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z et al. Secreted antibody\/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004; 279: 21343\u201321348.","journal-title":"J Biol Chem"},{"key":"BFbcj20134_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000074484","volume":"111","author":"F Andrade","year":"2004","unstructured":"Andrade F, Casciola-Rosen LA, Rosen A . Granzyme B-induced cell death. Acta Haematol 2004; 111: 28\u201341.","journal-title":"Acta Haematol"},{"key":"BFbcj20134_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1091\/mbc.e05-07-0631","volume":"17","author":"K Veugelers","year":"2006","unstructured":"Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC . Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006; 17: 623\u2013633.","journal-title":"Mol Biol Cell"},{"key":"BFbcj20134_CR11","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1038\/sj.onc.1210197","volume":"26","author":"X Jiang","year":"2007","unstructured":"Jiang X, Ellison SJ, Alarid ET, Shapiro DJ . Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007; 26: 4106\u20134114.","journal-title":"Oncogene"},{"key":"BFbcj20134_CR12","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1158\/1078-0432.CCR-05-0306","volume":"11","author":"IS van Houdt","year":"2005","unstructured":"van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11: 6400\u20136407.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20134_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2012.01.017","volume":"77","author":"C Soriano","year":"2012","unstructured":"Soriano C, Mukaro V, Hodge G, Ahern J, Holmes M, Jersmann H et al. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion? Lung Cancer 2012; 77: 38\u201345.","journal-title":"Lung Cancer"},{"key":"BFbcj20134_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/pros.21486","volume":"72","author":"M Ray","year":"2012","unstructured":"Ray M, Hostetter DR, Loeb CR, Simko J, Craik CS . Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis. Prostate 2012; 72: 846\u2013855.","journal-title":"Prostate"},{"key":"BFbcj20134_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.V99.1.232","volume":"99","author":"BA Bladergroen","year":"2002","unstructured":"Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232\u2013237.","journal-title":"Blood"},{"key":"BFbcj20134_CR16","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1182\/blood.V99.12.4540","volume":"99","author":"RL ten Berge","year":"2002","unstructured":"ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540\u20134546.","journal-title":"Blood"},{"key":"BFbcj20134_CR17","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/prot.24133","volume":"80","author":"V Losasso","year":"2012","unstructured":"Losasso V, Schiffer S, Barth S, Carloni P . Design of human granzyme B variants resistant to serpin B9. Proteins 2012; 80: 2514\u20132522.","journal-title":"Proteins"},{"key":"BFbcj20134_CR18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00262-012-1219-3","volume":"61","author":"A Pardo","year":"2012","unstructured":"Pardo A, Stocker M, Kampmeier F, Melmer G, Fischer R, Thepen T et al. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 2012; 61: 1617\u20131626.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbcj20134_CR19","doi-asserted-by":"publisher","first-page":"15177","DOI":"10.1074\/jbc.M006645200","volume":"276","author":"J Sun","year":"2001","unstructured":"Sun J, Whisstock JC, Harriott P, Walker B, Novak A, Thompson PE et al. Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. J Biol Chem 2001; 276: 15177\u201315184.","journal-title":"J Biol Chem"},{"key":"BFbcj20134_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.pep.2007.12.009","volume":"58","author":"M Stocker","year":"2008","unstructured":"Stocker M, Pardo A, Hetzel C, Reutelingsperger C, Fischer R, Barth S . Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expr Purif 2008; 58: 325\u2013331.","journal-title":"Protein Expr Purif"},{"key":"BFbcj20134_CR21","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V95.12.3909","volume":"95","author":"S Barth","year":"2000","unstructured":"Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909\u20133914.","journal-title":"Blood"},{"key":"BFbcj20134_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1046\/j.1440-1711.1999.00799.x","volume":"77","author":"KM Edwards","year":"1999","unstructured":"Edwards KM, Davis JE, Browne KA, Sutton VR, Trapani JA . Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immuno Cell Biol 1999; 77: 76\u201389.","journal-title":"Immuno Cell Biol"},{"key":"BFbcj20134_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.2910520610","volume":"52","author":"C von Kalle","year":"1992","unstructured":"von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer 1992; 52: 887\u2013891.","journal-title":"Int J Cancer"},{"key":"BFbcj20134_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/CJI.0b013e31816a2d23","volume":"31","author":"C Hetzel","year":"2008","unstructured":"Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stocker M . Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 31: 370\u2013376.","journal-title":"J Immunother"},{"key":"BFbcj20134_CR25","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s00259-010-1482-5","volume":"37","author":"F Kampmeier","year":"2010","unstructured":"Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R et al. Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nuc Med Mol Imaging 2010; 37: 1926\u20131934.","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"BFbcj20134_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1054\/bjoc.2000.1226","volume":"83","author":"A Klimka","year":"2000","unstructured":"Klimka A, Matthey B, Roovers RC, Barth S, Arends JW, Engert A et al. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Br J Cancer 2000; 83: 252\u2013260.","journal-title":"Br J Cancer"},{"key":"BFbcj20134_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1096\/fj.03-0901fje","volume":"18","author":"HP Hansen","year":"2004","unstructured":"Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP et al. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 2004; 18: 893\u2013895.","journal-title":"FASEB J"},{"key":"BFbcj20134_CR28","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812\u20131821.","journal-title":"N Engl J Med"},{"key":"BFbcj20134_CR29","doi-asserted-by":"publisher","first-page":"54275","DOI":"10.1074\/jbc.M411482200","volume":"279","author":"S Mahrus","year":"2004","unstructured":"Mahrus S, Kisiel W, Craik CS . Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 2004; 279: 54275\u201354282.","journal-title":"J Biol Chem"},{"key":"BFbcj20134_CR30","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2249.2006.03006.x","volume":"143","author":"CF Classen","year":"2006","unstructured":"Classen CF, Bird PI, Debatin KM . Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol 2006; 143: 534\u2013542.","journal-title":"Clin Exp Immunol"},{"key":"BFbcj20134_CR31","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","volume":"120","author":"E Tiacci","year":"2012","unstructured":"Tiacci E, Doring C, Brune V, van Noesel CJ, Klapper W, Mechtersheimer G et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609\u20134620.","journal-title":"Blood"},{"key":"BFbcj20134_CR32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V83.8.2045.2045","volume":"83","author":"HJ Gruss","year":"1994","unstructured":"Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG . Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045\u20132056.","journal-title":"Blood"},{"key":"BFbcj20134_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.onc.1202351","volume":"18","author":"D Krappmann","year":"1999","unstructured":"Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C . Molecular mechanisms of constitutive NF-kappaB\/Rel activation in Hodgkin\/Reed-Sternberg cells. Oncogene 1999; 18: 943\u2013953.","journal-title":"Oncogene"},{"key":"BFbcj20134_CR34","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2005-07-2880","volume":"107","author":"R Godal","year":"2006","unstructured":"Godal R, Keilholz U, Uharek L, Letsch A, Asemissen AM, Busse A et al. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood 2006; 107: 3205\u20133211.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj20134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj20134","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:48:13Z","timestamp":1672958893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3]]}},"alternative-id":["BFbcj20134"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2013.4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]},"assertion":[{"value":"30 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}